{"id":51591,"date":"2024-01-01T00:00:00","date_gmt":"2024-01-01T00:00:00","guid":{"rendered":"https:\/\/ibima.eu\/cd8nks-as-a-potential-biomarker-of-complete-response-and-survival-with-lenalidomide-plus-r-gdp-in-the-r2-gdp-gotel-trial-in-recurrent-refractory-diffuse-large-b-cell-lymphoma-frontiers-in-immunolog\/"},"modified":"2025-04-10T09:59:40","modified_gmt":"2025-04-10T09:59:40","slug":"cd8nks-as-a-potential-biomarker-of-complete-response-and-survival-with-lenalidomide-plus-r-gdp-in-the-r2-gdp-gotel-trial-in-recurrent-refractory-diffuse-large-b-cell-lymphoma-frontiers-in-immunolog","status":"publish","type":"post","link":"https:\/\/ibima.eu\/en\/cd8nks-as-a-potential-biomarker-of-complete-response-and-survival-with-lenalidomide-plus-r-gdp-in-the-r2-gdp-gotel-trial-in-recurrent-refractory-diffuse-large-b-cell-lymphoma-frontiers-in-immunolog\/","title":{"rendered":"CD8+NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent\/refractory diffuse large B cell lymphoma &#8211; FRONTIERS IN IMMUNOLOGY"},"content":{"rendered":"<p>Hontecillas-Prieto, L; Garc\u00eda-Dom\u00ednguez, DJ; Palaz\u00f3n-Carri\u00f3n, N; Garc\u00eda-Sancho, AM; Nogales-Fern\u00e1ndez, E; Jim\u00e9nez-Cortegana, C; S\u00e1nchez-Le\u00f3n, ML; Silva-Romeiro, S; Flores-Campos, R; Carnicero-Gonz\u00e1lez, F; R\u00edos-Herranz, E; de la Cruz-vicente, F; Rodr\u00edguez-Garc\u00eda, G; Fern\u00e1ndez-Alvarez, R; Mart\u00ednez-Banaclocha, N; Gum\u00e0-Padr\u00f2, J; G\u00f3mez-Codina, J; Salar-Silvestre, A; Rodr\u00edguez-Abreu, D; G\u00e1lvez-Carvajal, L; Labrador, J; Guirado-Risue\u00f1o, M; Provencio-Pulla, M; S\u00e1nchez-Beato, M; Marylene, L; Alvaro-Naranjo, T; Casanova-Espinosa, M; Rueda-Dom\u00ednguez, A; S\u00e1nchez-Margalet, V; de la Cruz-merino, L &#8211; 2024 &#8211; 10.3389\/fimmu.2024.1293931<\/p>","protected":false},"excerpt":{"rendered":"<p>Hontecillas-Prieto, L; Garc\u00eda-Dom\u00ednguez, DJ; Palaz\u00f3n-Carri\u00f3n, N; Garc\u00eda-Sancho, AM; Nogales-Fern\u00e1ndez, E; Jim\u00e9nez-Cortegana, C; S\u00e1nchez-Le\u00f3n, ML; Silva-Romeiro, S; Flores-Campos, R; Carnicero-Gonz\u00e1lez, F; R\u00edos-Herranz, E; de la Cruz-vicente, F; Rodr\u00edguez-Garc\u00eda, G; Fern\u00e1ndez-Alvarez, R; Mart\u00ednez-Banaclocha, N; Gum\u00e0-Padr\u00f2, J; G\u00f3mez-Codina, J; Salar-Silvestre, A; Rodr\u00edguez-Abreu, D; G\u00e1lvez-Carvajal, L; Labrador, J; Guirado-Risue\u00f1o, M; Provencio-Pulla, M; S\u00e1nchez-Beato, M; Marylene, L; Alvaro-Naranjo, T; Casanova-Espinosa, [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[1592],"tags":[],"class_list":["post-51591","post","type-post","status-publish","format-standard","hentry","category-publicaciones-b-01"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CD8+NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent\/refractory diffuse large B cell lymphoma - FRONTIERS IN IMMUNOLOGY - Ibima<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ibima.eu\/en\/cd8nks-as-a-potential-biomarker-of-complete-response-and-survival-with-lenalidomide-plus-r-gdp-in-the-r2-gdp-gotel-trial-in-recurrent-refractory-diffuse-large-b-cell-lymphoma-frontiers-in-immunolog\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CD8+NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent\/refractory diffuse large B cell lymphoma - FRONTIERS IN IMMUNOLOGY - Ibima\" \/>\n<meta property=\"og:description\" content=\"Hontecillas-Prieto, L; Garc\u00eda-Dom\u00ednguez, DJ; Palaz\u00f3n-Carri\u00f3n, N; Garc\u00eda-Sancho, AM; Nogales-Fern\u00e1ndez, E; Jim\u00e9nez-Cortegana, C; S\u00e1nchez-Le\u00f3n, ML; Silva-Romeiro, S; Flores-Campos, R; Carnicero-Gonz\u00e1lez, F; R\u00edos-Herranz, E; de la Cruz-vicente, F; Rodr\u00edguez-Garc\u00eda, G; Fern\u00e1ndez-Alvarez, R; Mart\u00ednez-Banaclocha, N; Gum\u00e0-Padr\u00f2, J; G\u00f3mez-Codina, J; Salar-Silvestre, A; Rodr\u00edguez-Abreu, D; G\u00e1lvez-Carvajal, L; Labrador, J; Guirado-Risue\u00f1o, M; Provencio-Pulla, M; S\u00e1nchez-Beato, M; Marylene, L; Alvaro-Naranjo, T; Casanova-Espinosa, [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ibima.eu\/en\/cd8nks-as-a-potential-biomarker-of-complete-response-and-survival-with-lenalidomide-plus-r-gdp-in-the-r2-gdp-gotel-trial-in-recurrent-refractory-diffuse-large-b-cell-lymphoma-frontiers-in-immunolog\/\" \/>\n<meta property=\"og:site_name\" content=\"Ibima\" \/>\n<meta property=\"article:published_time\" content=\"2024-01-01T00:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-10T09:59:40+00:00\" \/>\n<meta name=\"author\" content=\"prodriguez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"prodriguez\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/cd8nks-as-a-potential-biomarker-of-complete-response-and-survival-with-lenalidomide-plus-r-gdp-in-the-r2-gdp-gotel-trial-in-recurrent-refractory-diffuse-large-b-cell-lymphoma-frontiers-in-immunolog\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/cd8nks-as-a-potential-biomarker-of-complete-response-and-survival-with-lenalidomide-plus-r-gdp-in-the-r2-gdp-gotel-trial-in-recurrent-refractory-diffuse-large-b-cell-lymphoma-frontiers-in-immunolog\\\/\"},\"author\":{\"name\":\"prodriguez\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\"},\"headline\":\"CD8+NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent\\\/refractory diffuse large B cell lymphoma &#8211; FRONTIERS IN IMMUNOLOGY\",\"datePublished\":\"2024-01-01T00:00:00+00:00\",\"dateModified\":\"2025-04-10T09:59:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/cd8nks-as-a-potential-biomarker-of-complete-response-and-survival-with-lenalidomide-plus-r-gdp-in-the-r2-gdp-gotel-trial-in-recurrent-refractory-diffuse-large-b-cell-lymphoma-frontiers-in-immunolog\\\/\"},\"wordCount\":122,\"commentCount\":0,\"articleSection\":[\"Publicaciones - B-01\"],\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/ibima.eu\\\/cd8nks-as-a-potential-biomarker-of-complete-response-and-survival-with-lenalidomide-plus-r-gdp-in-the-r2-gdp-gotel-trial-in-recurrent-refractory-diffuse-large-b-cell-lymphoma-frontiers-in-immunolog\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/cd8nks-as-a-potential-biomarker-of-complete-response-and-survival-with-lenalidomide-plus-r-gdp-in-the-r2-gdp-gotel-trial-in-recurrent-refractory-diffuse-large-b-cell-lymphoma-frontiers-in-immunolog\\\/\",\"url\":\"https:\\\/\\\/ibima.eu\\\/cd8nks-as-a-potential-biomarker-of-complete-response-and-survival-with-lenalidomide-plus-r-gdp-in-the-r2-gdp-gotel-trial-in-recurrent-refractory-diffuse-large-b-cell-lymphoma-frontiers-in-immunolog\\\/\",\"name\":\"CD8+NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent\\\/refractory diffuse large B cell lymphoma - FRONTIERS IN IMMUNOLOGY - Ibima\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#website\"},\"datePublished\":\"2024-01-01T00:00:00+00:00\",\"dateModified\":\"2025-04-10T09:59:40+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/cd8nks-as-a-potential-biomarker-of-complete-response-and-survival-with-lenalidomide-plus-r-gdp-in-the-r2-gdp-gotel-trial-in-recurrent-refractory-diffuse-large-b-cell-lymphoma-frontiers-in-immunolog\\\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ibima.eu\\\/cd8nks-as-a-potential-biomarker-of-complete-response-and-survival-with-lenalidomide-plus-r-gdp-in-the-r2-gdp-gotel-trial-in-recurrent-refractory-diffuse-large-b-cell-lymphoma-frontiers-in-immunolog\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/cd8nks-as-a-potential-biomarker-of-complete-response-and-survival-with-lenalidomide-plus-r-gdp-in-the-r2-gdp-gotel-trial-in-recurrent-refractory-diffuse-large-b-cell-lymphoma-frontiers-in-immunolog\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/ibima.eu\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CD8+NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent\\\/refractory diffuse large B cell lymphoma &#8211; FRONTIERS IN IMMUNOLOGY\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/ibima.eu\\\/es\\\/\",\"name\":\"Ibima\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ibima.eu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\",\"name\":\"prodriguez\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"caption\":\"prodriguez\"},\"sameAs\":[\"https:\\\/\\\/ibima.eu\"],\"url\":\"https:\\\/\\\/ibima.eu\\\/en\\\/author\\\/prodriguez\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CD8+NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent\/refractory diffuse large B cell lymphoma - FRONTIERS IN IMMUNOLOGY - Ibima","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ibima.eu\/en\/cd8nks-as-a-potential-biomarker-of-complete-response-and-survival-with-lenalidomide-plus-r-gdp-in-the-r2-gdp-gotel-trial-in-recurrent-refractory-diffuse-large-b-cell-lymphoma-frontiers-in-immunolog\/","og_locale":"en_GB","og_type":"article","og_title":"CD8+NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent\/refractory diffuse large B cell lymphoma - FRONTIERS IN IMMUNOLOGY - Ibima","og_description":"Hontecillas-Prieto, L; Garc\u00eda-Dom\u00ednguez, DJ; Palaz\u00f3n-Carri\u00f3n, N; Garc\u00eda-Sancho, AM; Nogales-Fern\u00e1ndez, E; Jim\u00e9nez-Cortegana, C; S\u00e1nchez-Le\u00f3n, ML; Silva-Romeiro, S; Flores-Campos, R; Carnicero-Gonz\u00e1lez, F; R\u00edos-Herranz, E; de la Cruz-vicente, F; Rodr\u00edguez-Garc\u00eda, G; Fern\u00e1ndez-Alvarez, R; Mart\u00ednez-Banaclocha, N; Gum\u00e0-Padr\u00f2, J; G\u00f3mez-Codina, J; Salar-Silvestre, A; Rodr\u00edguez-Abreu, D; G\u00e1lvez-Carvajal, L; Labrador, J; Guirado-Risue\u00f1o, M; Provencio-Pulla, M; S\u00e1nchez-Beato, M; Marylene, L; Alvaro-Naranjo, T; Casanova-Espinosa, [&hellip;]","og_url":"https:\/\/ibima.eu\/en\/cd8nks-as-a-potential-biomarker-of-complete-response-and-survival-with-lenalidomide-plus-r-gdp-in-the-r2-gdp-gotel-trial-in-recurrent-refractory-diffuse-large-b-cell-lymphoma-frontiers-in-immunolog\/","og_site_name":"Ibima","article_published_time":"2024-01-01T00:00:00+00:00","article_modified_time":"2025-04-10T09:59:40+00:00","author":"prodriguez","twitter_card":"summary_large_image","twitter_misc":{"Written by":"prodriguez"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ibima.eu\/cd8nks-as-a-potential-biomarker-of-complete-response-and-survival-with-lenalidomide-plus-r-gdp-in-the-r2-gdp-gotel-trial-in-recurrent-refractory-diffuse-large-b-cell-lymphoma-frontiers-in-immunolog\/#article","isPartOf":{"@id":"https:\/\/ibima.eu\/cd8nks-as-a-potential-biomarker-of-complete-response-and-survival-with-lenalidomide-plus-r-gdp-in-the-r2-gdp-gotel-trial-in-recurrent-refractory-diffuse-large-b-cell-lymphoma-frontiers-in-immunolog\/"},"author":{"name":"prodriguez","@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635"},"headline":"CD8+NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent\/refractory diffuse large B cell lymphoma &#8211; FRONTIERS IN IMMUNOLOGY","datePublished":"2024-01-01T00:00:00+00:00","dateModified":"2025-04-10T09:59:40+00:00","mainEntityOfPage":{"@id":"https:\/\/ibima.eu\/cd8nks-as-a-potential-biomarker-of-complete-response-and-survival-with-lenalidomide-plus-r-gdp-in-the-r2-gdp-gotel-trial-in-recurrent-refractory-diffuse-large-b-cell-lymphoma-frontiers-in-immunolog\/"},"wordCount":122,"commentCount":0,"articleSection":["Publicaciones - B-01"],"inLanguage":"en-GB","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ibima.eu\/cd8nks-as-a-potential-biomarker-of-complete-response-and-survival-with-lenalidomide-plus-r-gdp-in-the-r2-gdp-gotel-trial-in-recurrent-refractory-diffuse-large-b-cell-lymphoma-frontiers-in-immunolog\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ibima.eu\/cd8nks-as-a-potential-biomarker-of-complete-response-and-survival-with-lenalidomide-plus-r-gdp-in-the-r2-gdp-gotel-trial-in-recurrent-refractory-diffuse-large-b-cell-lymphoma-frontiers-in-immunolog\/","url":"https:\/\/ibima.eu\/cd8nks-as-a-potential-biomarker-of-complete-response-and-survival-with-lenalidomide-plus-r-gdp-in-the-r2-gdp-gotel-trial-in-recurrent-refractory-diffuse-large-b-cell-lymphoma-frontiers-in-immunolog\/","name":"CD8+NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent\/refractory diffuse large B cell lymphoma - FRONTIERS IN IMMUNOLOGY - Ibima","isPartOf":{"@id":"https:\/\/ibima.eu\/es\/#website"},"datePublished":"2024-01-01T00:00:00+00:00","dateModified":"2025-04-10T09:59:40+00:00","author":{"@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635"},"breadcrumb":{"@id":"https:\/\/ibima.eu\/cd8nks-as-a-potential-biomarker-of-complete-response-and-survival-with-lenalidomide-plus-r-gdp-in-the-r2-gdp-gotel-trial-in-recurrent-refractory-diffuse-large-b-cell-lymphoma-frontiers-in-immunolog\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ibima.eu\/cd8nks-as-a-potential-biomarker-of-complete-response-and-survival-with-lenalidomide-plus-r-gdp-in-the-r2-gdp-gotel-trial-in-recurrent-refractory-diffuse-large-b-cell-lymphoma-frontiers-in-immunolog\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ibima.eu\/cd8nks-as-a-potential-biomarker-of-complete-response-and-survival-with-lenalidomide-plus-r-gdp-in-the-r2-gdp-gotel-trial-in-recurrent-refractory-diffuse-large-b-cell-lymphoma-frontiers-in-immunolog\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/ibima.eu\/es\/"},{"@type":"ListItem","position":2,"name":"CD8+NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent\/refractory diffuse large B cell lymphoma &#8211; FRONTIERS IN IMMUNOLOGY"}]},{"@type":"WebSite","@id":"https:\/\/ibima.eu\/es\/#website","url":"https:\/\/ibima.eu\/es\/","name":"Ibima","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ibima.eu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Person","@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635","name":"prodriguez","image":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","caption":"prodriguez"},"sameAs":["https:\/\/ibima.eu"],"url":"https:\/\/ibima.eu\/en\/author\/prodriguez\/"}]}},"_links":{"self":[{"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/posts\/51591","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/comments?post=51591"}],"version-history":[{"count":1,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/posts\/51591\/revisions"}],"predecessor-version":[{"id":52657,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/posts\/51591\/revisions\/52657"}],"wp:attachment":[{"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/media?parent=51591"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/categories?post=51591"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/tags?post=51591"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}